Vimarsana
Biggest News Aggregation in the World

Month Outcomes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Month Outcomes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Month Outcomes Today - Breaking & Trending Today

Ciliatech's glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease - Vimarsana News

Ciliatech's glaucoma implant CID receives favorable opinion on treating both open and narrow angle forms of disease

First independent observations, presented by Dr. Leon Au, leading consultant ophthalmology and eye surgeon, during ICGS 2024 in Abu Dhabi, underscore CID’s strong potential as treatment option for glaucoma Substantial IOP lowering effect from stand-alone procedureSurgical placement of suprachoroidal device without p...

Telemedicine Strategy After MI Scores a Win in TELE-ACS - Vimarsana News

Telemedicine Strategy After MI Scores a Win in TELE-ACS

Patients went home with self-testing devices plus remote access to a cardiologist—readmissions, events, and symptoms improved.

Source: tctmd.com
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology - Vimarsana News

Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology

Prospective, long-term trial results are consistent with the significant body of published clinical evidence demonstrating the durable safety and effectiveness of procedures enabled with the OMNI...

Brolucizumab, Alternating Anti-VEGFs Extends nAMD Treatment Intervals - Vimarsana News

Brolucizumab, Alternating Anti-VEGFs Extends nAMD Treatment Intervals

Real-world data shows extended intervals with both brolucizumab alone or alternating anti-VEGF treatment regimens after 12 and 18 months in nAMD eyes.

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23 - Vimarsana News

Final Round of Late-Breaking Clinical Trial Results Announced at VIVA23

/PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and...